|
Effect of an ionic antineoplastic agent Cytoreg on blood chemistry in a Wistar rat model
Katiusca Villasana1, William Quintero2, Yepsys Montero3, Cristian Pino4, Oscar Uzcategui4, Geizon Torres5, Mariangel Prada5, Lewis Pozo6, William Bauta7, William Jimenez7
1 Biochemistry Laboratories, Department of Pathology, University of the Andes, Mérida, Venezuela
2 Department of Biology, Faculty of Science, University of the Andes, Mérida, Venezuela
3 Vivarium, University of the Andes, Mérida, Venezuela
4 Department of Technical and Experimental Surgery, Faculty of Medicine, University of the Andes, Mérida, Venezuela
5 Vitalis, Clinical Laboratory, Smart Health Laboratory, Merida, Venezuela
6 Cytorex de Venezuela SA, Maracaibo, Venezuela
7 Cytorex Biosciences, Inc., Weston, FL, USA
Correspondence Address:
Katiusca Villasana
Biochemistry Laboratories, Department of Pathology, University of the Andes, Mérida
Venezuela
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2045-9912.324592
|
|
Cytoreg is an ionic therapeutic agent comprising a mixture of hydrochloric, sulfuric, phosphoric, hydrofluoric, oxalic, and citric acids. In diluted form, it has demonstrated efficacy against human cancers in vitro and in vivo. Although Cytoreg is well tolerated in mice, rats, rabbits, and dogs by oral and intravenous administration, its mechanism of action is not documented. The acidic nature of Cytoreg could potentially disrupt the pH and levels of ions and dissolved gases in the blood. Here, we report the effects of the intravenous administration of Cytoreg on the arterial pH, oxygen and carbon dioxide pressures, and bicarbonate, sodium, potassium, and chloride concentrations. Our results demonstrate that Cytoreg does not disturb the normal blood pH, ion levels, or carbon dioxide content, but increases oxygen levels in rats. These data are consistent with the excellent tolerability of intravenous Cytoreg observed in rabbits, and dogs. The study was approved by the Bioethics Committee of the University of the Andes, Venezuela (CEBIOULA) (approval No. 125) on November 3, 2019.
|
